Epidermal growth factor receptor in glioblastoma
Journal Title: Folia Neuropathologica - Year 2005, Vol 43, Issue 3
Abstract
We compiled the current state of knowledge about the epidermal growth factor receptor (EGFR) in glioblastoma. Glioblastoma is one of the most common primary brain tumours and has an unfavourable prognosis despite aggressive treatment. These factors stimulate new research trials and a recent area of interest of neurooncologists is EGFR. This molecule is frequently altered in glioblastoma and constitutes the potential target for therapy. We decided to review the literature on biological structure of that molecule, its biological activity and the role in GBL with potential targeting it in the future neurooncological practice.
Authors and Affiliations
Antoni Żawrocki, Wojciech Biernat
Keywords
Related Articles
- EP ID EP112764
- DOI -
- Views 125
- Downloads 0
Interleukin-12 in acute ischemic stroke patients
Cytokines are important mediators of stroke-induced immunological/inflammatory reaction which contributes to brain infarct progression as well as to the disease severity and outcome. The aim of the study was to evaluat...
Inhibition of poly(ADP-ribose) polymerase activity protects hippocampal cells against morphological and ultrastructural alteration evoked by ischemia-reperfusion injury
Poly(ADP-ribose) polymerase 1 (PARP-1 EC 2.4.2.30) is a nuclear enzyme that plays an important role in cell survival and death. PARP is involved in DNA repair machinery, however, massive DNA damage leads to overactivatio...
Abstracts
Changes of cytoskeletal proteins in ischaemic brain under cardiac arrest and reperfusion conditions
The aim of the study was to assess the level of calpain and its endogenous substrates – microtubule-associated protein 2 (MAP-2) and fodrin in the rodent model of global cerebral ischaemia caused by temporary cardiac arr...
CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone)
The MCP-1 and RANTES levels were measured in 20 multiple sclerosis patients before and after 1 year daily treatment with 20 mg of subcutaneously applied glatiramer acetate. The level of MCP-1 in serum from multiple scler...